BeiGene, Ltd. (BGNE): Price and Financial Metrics
BeiGene, Ltd. (BGNE)
Today's Latest Price: $210.61 USD
Updated Aug 14 12:07pm
Add BGNE to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 215 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
BGNE Stock Summary
- With a market capitalization of $19,509,983,356, BeiGene Ltd has a greater market value than 90.22% of US stocks.
- With a price/sales ratio of 86.82, BeiGene Ltd has a higher such ratio than 96.8% of stocks in our set.
- As for revenue growth, note that BGNE's revenue has grown -48.23% over the past 12 months; that beats the revenue growth of merely 3.78% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to BeiGene Ltd are SRPT, XLRN, SGEN, BBIO, and FOLD.
- Visit BGNE's SEC page to see the company's official filings. To visit the company's web site, go to www.beigene.com.
BGNE Stock Price Chart Technical Analysis Charts
BGNE Price/Volume Stats
| Current price | $210.61 | 52-week high | $256.01 |
| Prev. close | $215.38 | 52-week low | $114.41 |
| Day low | $210.61 | Volume | 36,937 |
| Day high | $214.32 | Avg. volume | 302,505 |
| 50-day MA | $204.05 | Dividend yield | N/A |
| 200-day MA | $174.45 | Market Cap | 18.82B |
BeiGene, Ltd. (BGNE) Company Bio
BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops various oncology drugs in the People’s Republic of China. The company was founded in 2010 and is based in the Cayman Islands.
Loading social stream, please wait...